KROS

KEROS THERAPEUTICS INC

KROS·492327101·US·Common Stock·Healthcare - Biotechnology-Activist

KROS (KEROS THERAPEUTICS INC) is held by 91 institutional investors as of Q1 2026. Largest holders: BlackRock, Inc. ($26.6M), VANGUARD CAPITAL MANAGEMENT LLC ($9.2M), Qube Research & Technologies Ltd ($8M). Net institutional sentiment: Mixed.

91
Holders
Avg rating(21 Elite)
$161.5M
Total Value
49% (100)
Fund Consensus
46 buying - 48 selling
KROSSmart Money Verdict
View all
Held by 91 funds
21 elite
Who's Trading
InsiderNWNewton Charles W.Sell $6KJun 11, 2026
InsiderKJKnowles JuliusSell $28KJun 4, 2026
InsiderFNFarzan NimaSell $28KJun 4, 2026
InsiderSASeth AlpnaSell $28KJun 4, 2026
ActivistNANantahala Capital Management, LLC6.9%May 15, 2026
InsiderBJBIENAIME JEAN JACQUESBuy $12KApr 15, 2026
ActivistBlackRock, Inc.BlackRock, Inc.10.1%Apr 7, 2026
ActivistThe Vanguard GroupThe Vanguard Group0.0%Mar 27, 2026
InsiderBJBIENAIME JEAN JACQUESBuy $22KMar 9, 2026
InsiderSJSeehra JasbirSell $113KFeb 19, 2026
13F: Insider & Congress:
Fund
Action
Shares
Value
Weight
Est. P&L
Conviction
Increased
2.4M(+5.3%)$26.6M0.0%-23.55%
30
New
831,421$9.2M0.0%-11.94%
38
Decreased
724,926(-7.5%)$8M0.0%-35.68%
0
Decreased
706,071(-8.1%)$7.8M0.0%-22.26%
0
Increased
689,229(+5.3%)$7.6M0.0%-10.76%
29
New
682,043$7.5M0.0%-11.94%
38
Increased
681,460(+7.3%)$7.5M0.0%-71.38%
29
Decreased
590,249(-55.8%)$6.5M0.0%-38.90%
0
Decreased
561,730(-47.8%)$6.2M0.0%-71.56%
0
Decreased
509,608(-32.5%)$5.6M0.0%+4.12%
0
Decreased
453,482(-23.4%)$5M0.0%-36.32%
0
Decreased
406,666(-13.9%)$4.5M0.0%-41.12%
0
Increased
406,563(+125.2%)$4.5M0.0%-15.86%
43
Increased
363,835(+14.3%)$4M0.0%-36.21%
30
Increased
321,360(+453.9%)$3.5M0.0%-27.20%
43
Increased
262,075(+315.4%)$2.9M0.0%-7.61%
42
Decreased
257,884(-19.8%)$2.8M0.0%-11.87%
0
Increased
254,187(+1.4%)$2.8M0.0%-70.42%
27
Increased
238,618(+25.4%)$2.6M0.0%-14.60%
32
Decreased
224,479(-62.0%)$2.5M0.0%-20.06%
0

Showing 1-20 of 100

1 / 5

Other Healthcare stocks held by institutions

Data sourced from four SEC data sources: 13F, Form 4, 13D/13G, and STOCK Act. Not financial advice. Full disclaimer

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used